Detailed explanation of the selling price and purchasing channels of Dabrafenib/Dabrafenib
Dabrafenib, a cancer treatment drug containingdabrafenib as the active ingredient, is designed to treat adult cancer patients carrying a specific gene mutation called "BRAF V600". The drug can be used alone or in combination with trametinib to effectively fight various cancer types such as melanoma, advanced non-small cell lung cancer, and thyroid cancer that have spread or cannot be surgically removed.
Dabrafenib is available in two capsule forms: 50 mg and 75 mg. The recommended dosage is 150 mg twice a day and should be taken on an empty stomach (i.e. at least 1 hour before or 2 hours after a meal). Treatment with dabrafenib can be continued as long as the patient continues to benefit from treatment. For patients after surgery for advanced melanoma, continued treatment is usually recommended for 12 months unless the disease recurs. Of course, if a patient experiences certain side effects, they may need to temporarily interrupt treatment, reduce the dose, or stop taking the medication entirely.
Regarding the price and purchasing channels of dabrafenib, currently in the domestic market, the original research version of dabrafenib has been launched and successfully included in the medical insurance catalog. It is mainly available in two specifications: 50 mg 120-capsule package and 75 mg 120-capsule package. Each box may cost more than 10,000 yuan. Patients can consult and purchase this medicine at domestic hospitals or pharmacies.
In overseas markets, the price and purchasing channels of dabrafenib are different. For example, in Türkiye, the price of 75 mg dabrafenib in a 120-pellet package is about more than 7,000 yuan (note the possible price fluctuations caused by exchange rate changes). In addition, there are a variety of generic drugs of dabrafenib overseas, whose ingredients are similar to the original drug, but the price is more affordable. For example, the price of medicines of the same specifications produced in Laos may be as low as more than 2,000 yuan (also affected by the exchange rate, the price may change).
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)